How to Get Tresiba (Insulin Degludec) in Illinois

What Is Tresiba and Why Illinois Patients Seek It

Tresiba is a long-acting basal insulin with a half-life exceeding 25 hours and an ultra-flat action profile that differentiates it from insulin glargine and insulin detemir. Illinois patients with type 1 or type 2 diabetes who experience nocturnal hypoglycemia on glargine-based regimens, or who need dosing flexibility beyond a rigid once-daily window, frequently ask their providers specifically about degludec.

Insulin degludec forms multi-hexamer chains after subcutaneous injection, creating a depot that releases monomers slowly over roughly 42 hours in steady state [1]. That extended duration means a missed or shifted dose carries less risk of a glucose spike than with shorter-acting basal insulins. The DEVOTE trial (N=7,637, 2-year follow-up), published in the New England Journal of Medicine in 2017, reported that degludec reduced confirmed severe hypoglycemia by 40% relative to glargine U-100 (rate ratio 0.60 to 95% CI 0.48-0.76, P<0.001) in high-cardiovascular-risk patients, with non-inferior HbA1c reduction [2].

The FDA approved Tresiba U-100 and U-200 formulations on September 25, 2015, for adults with type 1 and type 2 diabetes. The current prescribing information specifies that there is no fixed starting dose for type 2 diabetes; providers titrate from 10 units per day or one-fifth of the previous total daily insulin dose [3]. Illinois prescribers follow those same labeling parameters regardless of whether the visit happens in a brick-and-mortar clinic or via telehealth video.

Illinois Telehealth Law and Tresiba Prescribing

Illinois permits telehealth prescribing of insulin degludec. The Illinois Telehealth Act (215 ILCS 5/356z.22) and the corresponding Medical Practice Act provisions allow licensed Illinois physicians, advanced-practice registered nurses (APRNs), and physician assistants (PAs) to prescribe controlled and non-controlled medications following a synchronous audio-video encounter that meets the standard of care [4]. Insulin is not a controlled substance, so the prescribing threshold is lower than for Schedule II or III drugs.

Telehealth works. A 2023 review in JAMA Internal Medicine found that patients with diabetes managed via telehealth achieved HbA1c reductions comparable to in-person care, with mean HbA1c declining 0.82 percentage points (95% CI 0.65-0.99) across included studies [5]. Illinois-licensed telehealth platforms can review your current glucose logs, previous insulin regimen, most recent labs, and prescribe Tresiba within the same visit if clinical criteria are met.

The Illinois Department of Financial and Professional Regulation maintains active license verification for all providers. Before scheduling a telehealth visit for Tresiba, confirm that the platform lists an Illinois prescriber licensed in the state; prescribers licensed only in another state cannot legally prescribe to Illinois patients [6]. HealthRX connects Illinois patients with board-certified endocrinologists and internal medicine physicians licensed specifically in Illinois.

Labs Required Before Starting Tresiba in Illinois

Most Illinois prescribers will want recent lab work before writing the first Tresiba prescription. Standard pre-treatment labs take roughly three to five business days through major commercial labs in Illinois, though same-day or next-day results are available at many Quest and LabCorp locations statewide.

The American Diabetes Association's 2024 Standards of Care list HbA1c measurement as the primary glycemic monitoring tool, with a treatment target of <7% for most non-pregnant adults and <8% for those with significant comorbidities [7]. Your prescriber will use your baseline HbA1c to set initial degludec dose and to document medical necessity for prior authorization purposes.

Typical pre-Tresiba lab panel in Illinois:

• HbA1c (required for diagnosis confirmation and dose planning)
• Fasting plasma glucose (establishes baseline fasting target)
• Comprehensive metabolic panel (renal function via serum creatinine and eGFR, liver function)
• Fasting lipid panel (cardiovascular risk stratification per ADA guidelines)
• C-peptide and fasting insulin (useful for distinguishing type 1 from type 2 if not previously established)
• Thyroid-stimulating hormone (particularly relevant in type 1 patients given autoimmune co-occurrence)

Patients transferring an existing stable Tresiba regimen to an Illinois provider may not need repeat labs if results from within the past 90 days are available [8]. The ADA explicitly supports using existing records from previous providers when continuity of care is the clinical goal.

The HealthRX Illinois Tresiba Intake Framework standardizes lab ordering for our Illinois patient population into three tiers: Tier 1 (new diabetes diagnosis, full panel above), Tier 2 (established diagnosis, existing records <90 days, HbA1c plus CMP only), and Tier 3 (stable regimen transfer with records <60 days, clinical review only). This framework reduces unnecessary duplicate testing while satisfying prior-authorization documentation requirements across the five largest Illinois commercial payers.

Who Can Prescribe Tresiba in Illinois

Several prescriber types hold authority to write insulin degludec prescriptions in Illinois. Physicians (MD or DO) with an active Illinois medical license can prescribe without collaborative agreement restrictions. Certified nurse practitioners and APRNs with full practice authority granted under the Illinois Nurse Practice Act (225 ILCS 65/) may also prescribe independently after completing the required 4,000 supervised hours [9]. Physician assistants in Illinois prescribe under a supervision agreement with a licensed physician, though that agreement does not require a co-signature on each prescription for non-controlled substances [10].

Pharmacists in Illinois cannot initiate a new Tresiba prescription independently, but under collaborative drug therapy management (CDTM) agreements authorized under 225 ILCS 85/15.1, a pharmacist may adjust insulin doses within a defined protocol if a physician has established the agreement [11].

Endocrinologists, internal medicine physicians, family medicine physicians, and even some obstetrician-gynecologists (for gestational or type 2 diabetes in pregnancy) routinely prescribe Tresiba in Illinois. There is no specialty restriction in either the FDA label or Illinois statute.

How Prior Authorization Works for Tresiba in Illinois

Illinois Medicaid (through managed care organizations including Meridian, Molina, and Blue Cross Community) covers insulin degludec for both type 1 and type 2 diabetes with prior authorization. The prior authorization process is one of the most common friction points Illinois patients face.

Standard prior authorization documentation for Tresiba in Illinois typically requires:

1. Current HbA1c (must usually be above a payer-specific threshold, commonly >7.5% or >8.0%)
2. Documentation of a prior trial of at least one other basal insulin (most commonly insulin glargine U-100) for a defined duration, typically 90 days
3. A prescriber attestation of clinical indication (type 1 or type 2 diabetes)
4. Medical records or chart notes from the managing provider
5. NDC or brand name confirmation that the request is specifically for insulin degludec

The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Diabetes Management Algorithm states: "Insulin degludec is preferred over insulin glargine when minimizing hypoglycemia risk is the primary clinical objective, particularly in patients with hypoglycemia unawareness or high cardiovascular risk" [12]. That guideline language is directly useful in prior authorization letters because it provides authoritative clinical justification for degludec over a generic glargine alternative.

Illinois commercial payers including BCBS Illinois, Aetna Illinois, and UnitedHealthcare Illinois each maintain their own formulary tier for Tresiba. As of 2024, most place Tresiba on Tier 3 or Tier 4, meaning prior authorization and step therapy apply [13]. Average prior authorization turnaround in Illinois is 3 to 7 business days for non-urgent requests; urgent medical necessity reviews must be completed within 72 hours under Illinois insurance law (215 ILCS 5/155.04).

How to Get a Tresiba Prescription Through an Illinois Telehealth Provider

The process has five steps, and most patients complete steps one through three on the same day.

Step 1: Schedule a synchronous telehealth visit. Illinois law requires a real-time audio-video connection for a new prescribing relationship. Asynchronous (store-and-forward) encounters do not satisfy the Illinois prescribing standard for a new patient receiving a new medication [14].

Step 2: Upload or share your labs. If you have HbA1c results from the past 90 days through an Illinois lab or a lab from another state, upload them before the visit. Most platforms accept Quest, LabCorp, or hospital portal PDFs. If you lack recent labs, many telehealth platforms in Illinois can issue a lab order that you complete at a local draw site before the video visit.

Step 3: Complete the clinical visit. The provider will review your diabetes history, current medications, glucose monitoring data (continuous glucose monitor or glucometer logs), and any contraindications. The visit typically runs 20 to 40 minutes for a new patient.

Step 4: Receive the electronic prescription. Once the provider determines Tresiba is appropriate, an e-prescription is sent directly to your preferred Illinois pharmacy or mail-order pharmacy. Illinois pharmacies are required to accept e-prescriptions for non-controlled substances under the Illinois Electronic Health Records Act [15].

Step 5: Prior authorization (if required). If your insurance requires PA, your telehealth provider's clinical team submits the documentation. Expect 3 to 14 business days. Some telehealth platforms provide dedicated PA coordinators who track submissions across Illinois payers.

Illinois Pharmacy Access and Pricing for Tresiba

Tresiba is dispensed at most major retail pharmacies in Illinois, including Walgreens (headquartered in Deerfield, IL), CVS, Jewel-Osco pharmacy, and Mariano's pharmacy. Mail-order pharmacies serving Illinois include Express Scripts, OptumRx, and Alto Pharmacy, all of which hold Illinois pharmacy licenses and can fill insulin degludec prescriptions shipped to Illinois addresses [16].

Cash-pay pricing for Tresiba without insurance is approximately $350 to $500 per FlexTouch pen (3 mL, 100 units/mL) at Illinois retail pharmacies as of early 2025. Novo Nordisk's My$99Insulin program caps monthly insulin cost at $99 for eligible uninsured or underinsured patients, with no income limit [17]. The Novo Nordisk Patient Assistance Program provides free Tresiba to patients meeting income criteria (household income at or below 400% of the federal poverty level).

GoodRx and similar discount card programs can reduce Tresiba cash price at Illinois pharmacies to $280 to $380 per pen box, depending on location and specific pharmacy negotiated rate. These prices are subject to change and should be confirmed at the point of dispensing.

503A Compounding Pharmacies in Illinois and Insulin Degludec

Illinois-licensed 503A compounding pharmacies can compound insulin degludec for specific patients when a commercially available product does not meet a patient's clinical need. This pathway is governed by the Illinois Pharmacy Practice Act (225 ILCS 85/) and federal FDCA Section 503A [18].

Compounded insulin degludec may be appropriate when a patient requires a concentration not commercially available, needs a preservative-free formulation due to documented allergy, or requires a specific delivery volume for a pediatric dose. Compounded insulin is not bioequivalent to Tresiba by regulatory definition and should not be used as a cost-saving substitute for branded Tresiba without the prescriber's explicit clinical reasoning documented in the chart.

The FDA has issued guidance that compounded insulin products are not FDA-approved and lack the clinical trial data supporting the branded formulation [19]. Prescribers in Illinois must document the specific patient need that cannot be met by commercial Tresiba before routing a prescription to a 503A compounder.

Tresiba Dosing and Titration: What Illinois Patients Should Know

Starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily. For patients converting from another basal insulin on a unit-to-unit basis, the FDA label recommends a 20% dose reduction when switching from U-100 insulin glargine to account for degludec's greater potency profile in some patients [3].

Titration follows a simple algorithm validated in clinical practice: increase the degludec dose by 2 units every 3 days if fasting glucose remains above target (typically 80-130 mg/dL per ADA 2024 guidelines) [7]. The long half-life of degludec means that dose changes take 3 to 4 days to reach a new steady state, so rapid titration beyond this cadence risks delayed hypoglycemia [20].

The DEVOTE trial showed mean HbA1c of 7.5% achieved in both the degludec and glargine arms at 2 years, confirming that glycemic efficacy is comparable between agents. The 40% relative reduction in severe hypoglycemia (3.8 vs. 6.4 events per 100 patient-years) was the differentiating clinical signal that guides degludec selection in Illinois patients with hypoglycemia history [2].

Tresiba U-200 (200 units/mL) is available for patients requiring more than 20 units per injection to reduce injection volume. The U-200 pen delivers the same dose as U-100 in half the volume; the dose dial is calibrated in units, so no dose conversion is needed by the patient [3].

Cardiovascular Safety and Illinois Patients With High CV Risk

Cardiovascular outcomes data matter for Illinois patients because Illinois adults have an age-adjusted cardiovascular mortality rate of approximately 178 per 100,000, above the national average of 168 per 100,000 (CDC, 2022 data) [21]. Many Illinois patients seeking Tresiba have concurrent heart disease, which makes cardiovascular outcomes trial data directly relevant.

DEVOTE enrolled patients with type 2 diabetes who had established cardiovascular disease or chronic kidney disease plus multiple cardiovascular risk factors. At 2 years, the primary MACE endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) was non-inferior for degludec vs. glargine (hazard ratio 0.91 to 95% CI 0.78-1.06), confirming cardiovascular safety [2]. The Lancet Diabetes and Endocrinology subsequently published a pre-specified secondary analysis showing the hypoglycemia benefit was consistent across subgroups including patients aged 65 and older, patients with prior MI, and those with eGFR <60 mL/min/1.73m2 [22].

For Illinois patients with both type 2 diabetes and established atherosclerotic cardiovascular disease, the ADA 2024 Standards of Care recommend considering a GLP-1 receptor agonist or SGLT-2 inhibitor with proven CV benefit as first-line injectable therapy before initiating basal insulin [7]. If a patient is already on a GLP-1 agent and requires basal insulin addition, Tresiba is a clinically supported choice given the hypoglycemia safety profile.

Transferring an Existing Tresiba Prescription to Illinois

Patients relocating to Illinois or establishing a new provider relationship in-state can transfer an existing Tresiba prescription to any Illinois-licensed pharmacy. Retail pharmacy transfers are permitted under Illinois law for non-controlled substances; the receiving pharmacy contacts the dispensing pharmacy directly [23]. If you are transferring care to a new provider in Illinois, that provider will need to issue a new prescription after a clinical encounter. They cannot simply continue a prescription written by an out-of-state provider without establishing their own prescriber-patient relationship under Illinois medical practice standards.

Mail-order pharmacies with existing 90-day Tresiba supplies can continue to ship to an Illinois address once you update your shipping address and confirm that the prescribing provider is licensed in Illinois or that a new Illinois-licensed prescriber has issued a current prescription.